about
Neutrophil extracellular traps in sepsis.Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity.Pregnancy failure in patients with obstetric antiphospholipid syndrome with conventional treatment: the influence of a triple positive antibody profile.Soluble thrombomodulin levels among women with a history of recurrent pregnancy loss, with or without antiphospholipid antibodies.The -2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene (MCP-1) is associated with an increased risk of rheumatoid arthritis in Argentine patients.tagSNP rs1495741 as a useful molecular marker to predict antituberculosis drug-induced hepatotoxicity.The -308 G/A polymorphism in the tumor necrosis factor-α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients.Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs.Association between the acquired free protein S deficiency in HIV-infected patients with the lipid profile levels.[Plasma homocysteine in human immunodeficiency virus infected patient].D-Dimer as a prognostic marker of morbidity and mortality among HIV patients: a call for attention.Thrombophilia in human immunodeficiency virus-infected patients with osteonecrosis: Is there a real connection? The first case-control study.Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients.[Insulin-like growth factor-binding protein-1: a new biochemical marker of nonalcoholic fatty liver disease?].False positive reactions in confirmatory tests for syphilis in presence of antiphospholipid antibodies: misdiagnosis with prognostic and social consequences.Maternal carriers of the ANXA5 M2 haplotype are exposed to a greater risk for placenta-mediated pregnancy complications.Activated protein C resistance in patients with arterial ischemic strokeHigh prevalence of antiphospholipid antibodies in leprosy: evaluation of antigen reactivity.Different types of antiphospholipid antibodies in AIDS: a comparison with syphilis and the antiphospholipid syndromeAntibodies to tissue factor pathway inhibitor are uncommonly detected in patients with infection-related antiphospholipid antibodiesThe range of normal values of liver enzymes in the era of metabolic syndrome: the need for a redefinitionCirculating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodiesRelationship between 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene and obesity in Argentinian Hispanic adultsAnti-β2glycoprotein I antibodies from leprosy patients do not show thrombogenic effects in an in vivo animal modelThe -2518 A/G polymorphism in the monocyte chemoattractant protein 1 gene is associated with the risk of developing systemic lupus erythematosus in Argentinean patients: a multicenter study4G/5G plasminogen activator inhibitor-1 and -308 A/G tumor necrosis factor-α promoter gene polymorphisms in Argentinean lupus patients: focus on lupus nephritisThe distribution of allelic and genotypic frequencies of N-Acetyltransferase-2 variants in an Argentine populationPaternal factor V Leiden and recurrent pregnancy loss: a new concept behind fetal genetics? ReplyInherited thrombophilia and pregnancy loss. Study of an Argentinian cohortPaternal factor V Leiden and recurrent pregnancy loss: a new concept behind fetal genetics?What is the best time to assess the antiphospholipid antibodies (aPL) profile to better predict the obstetric outcome in antiphospholipid syndrome (APS) patients?A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome
P50
Q38227298-4DD0D553-6A4D-48EE-9FDB-D1A763DB9A27Q38629014-3D9C9F3D-8E8B-4AE9-8BA1-C3124AB86523Q40341423-930F960F-2819-4EBE-904F-50DAB872833EQ40454444-68456B74-54FC-4236-8E9B-692295DCA23EQ40573679-629BDEAF-1F9E-4C51-8E96-07D0207B522FQ40703310-76510A49-1E69-4597-8194-175291401A15Q42221977-3972DEF4-E519-4A40-BC3C-3CAA68A7DA4BQ42284821-900D9A66-B5AA-434E-9F60-EE7BF04F93CAQ43487309-462BBCF8-6316-4B1F-A036-A304CC93C055Q44662689-53B619BF-F06A-4FDF-9309-D8BA94EBA9EEQ45049681-A18EA6A1-2A37-4054-8C53-7F7AD140542FQ45398113-9E4A0FD1-155B-4460-9D97-953B8C301D22Q45729419-AB088D30-07BF-46E3-8006-58A490374314Q46028988-364A313C-9D3E-4F61-B46D-35657A28DEDFQ48425505-B5F9392B-7627-4E31-AAAA-97FDA109DCD4Q52677785-26B2A84A-D92D-4DFC-918A-47014D0FF7DBQ58841384-153C3DE9-86B2-4BB5-90E3-6ACE53F2D055Q64884874-9DA78E2E-397B-473B-91DC-3DCBAFDF8324Q73163209-0DE6393C-F95B-4DB0-9CFA-274B22769303Q79105371-C7491128-CA35-4638-A60A-DC3E1BF9E07FQ81244515-05EBC80B-7D0E-4C46-B9F4-3A5D7027E717Q81486591-519AFE2D-BC06-4226-9F10-9A4E6EB97A2CQ82717509-DED9BC9E-79E2-4EB1-BFF4-3F30110620F3Q83249196-D09E9554-C0C7-4545-9DB7-D4900F506FE7Q83784585-CCB51976-1DA0-4BE1-AD97-0C512FC1344BQ85410500-A924EBB3-36AB-4CA0-923F-7813FDF8EB73Q87353375-872CCC01-F6BA-46B9-95B4-679D5FB8E14AQ87561698-C6071E69-F62A-4AA8-8F21-1A06DBC76D05Q88012539-2B62BB0E-6F9D-4DF8-B10D-EAC41506BE21Q88180587-7754CA72-B3CA-46C6-AD93-5C1750675B98Q91217007-910CB365-D081-4194-9E88-CECAECD1AFF6Q92232877-F31F0AD4-C3CB-4E69-A730-55A54C88D82C
P50
description
researcher ORCID ID = 0000-0002-2527-7298
@en
wetenschapper
@nl
name
Gabriela F de Larrañaga
@ast
Gabriela F de Larrañaga
@en
Gabriela F de Larrañaga
@es
Gabriela F de Larrañaga
@nl
type
label
Gabriela F de Larrañaga
@ast
Gabriela F de Larrañaga
@en
Gabriela F de Larrañaga
@es
Gabriela F de Larrañaga
@nl
prefLabel
Gabriela F de Larrañaga
@ast
Gabriela F de Larrañaga
@en
Gabriela F de Larrañaga
@es
Gabriela F de Larrañaga
@nl
P106
P1153
6701830502
P21
P31
P496
0000-0002-2527-7298